20-Bio-A1 Biomaterials and Biocompatibility · December 2014
Nivaar worked solution (AI-drafted; not reviewed by a licensed engineer)
Paper format: National Exams, December 2014 — 04-Bio-A1 Biomaterials and Biocompatibility. Three hours, open book, any non-communicating calculator. Seven questions of equal value (20 marks each, 100 marks total); five constitute a complete paper and only the first five appearing in the answer book are marked. All seven are solved here, because this set is a study resource rather than an examination script. Every question is qualitative/descriptive (materials selection, surface science, host response) rather than numerical, except Question 7, which asks for an engineering interpretation of a small stress–strain data set — that question therefore quotes and reasons from the given numbers while still answering in flowing prose, as the question itself calls for discussion rather than a computed final answer.
Reference texts (the books an open-book candidate should have on the desk for this subject):
Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.
Large-diameter arterial replacement succeeds with Dacron/PTFE largely because high volumetric flow and correspondingly high wall shear rate keep the luminal surface relatively free of adherent thrombus, and because the lumen is large enough that even a thin layer of neointima or mural thrombus on the graft wall removes only a small fraction of the cross-sectional flow area. Below about 5–6 mm diameter, three problems compound: first, flow rate and wall shear stress in this size range are much lower, which favours platelet adhesion, aggregation, and thrombus formation on the synthetic (non-endothelialized) luminal surface; second, none of the standard synthetic grafts spontaneously develop a confluent, functional endothelial monolayer — the natural, non-thrombogenic lining every native vessel has — so the graft surface remains permanently thrombogenic rather than becoming biologically "invisible" to blood; and third, the mechanical compliance mismatch between a stiff synthetic tube and the compliant native artery it is anastomosed to creates a localized, disturbed-flow zone at the suture line that drives intimal hyperplasia (smooth-muscle-cell proliferation), progressively narrowing the graft precisely where the smaller lumen can least tolerate it. Because even a thin layer of thrombus or hyperplastic tissue removes a much larger fraction of a small lumen than of a large one, small-diameter grafts occlude at a rate that has made them clinically unusable, and native vein (with its own endothelium and compliant wall) remains the only reliable option. The goal has not been achieved because no material yet reliably delivers all three requirements together — a durable, functional, non-thrombogenic endothelium; mechanical compliance matched to the native artery; and adequate long-term structural durability — simultaneously in a low-flow, low-shear environment.
Option 1 — endothelial cell seeding / lining. Autologous endothelial cells (harvested from the patient, e.g. from a vein segment or, more recently, from circulating endothelial progenitor cells) are seeded onto the luminal surface before implantation, aiming to reconstitute the natural non-thrombogenic endothelial monolayer that native vessels rely on. This has strong theoretical potential because it addresses the root cause directly rather than merely reducing thrombogenicity indirectly. The engineering challenges are substantial: achieving a confluent monolayer that adheres firmly enough to resist detachment under arterial shear stress once flow starts; the delay and cost of a two-stage procedure (harvest and expand cells, then implant); ensuring the seeded cells retain a normal, anti-thrombotic phenotype after in-vitro expansion; and pre-treating the graft surface (e.g. with fibronectin or an engineered peptide coating) to promote cell adhesion in the first place.
Option 2 — surface-immobilized or eluting anticoagulant (e.g. covalently bound heparin). Heparin (or another antiplatelet/anticoagulant agent) is either physically adsorbed, ionically bonded, or covalently immobilized to the graft's luminal surface, locally inhibiting the coagulation cascade and platelet activation at the blood–material interface without the systemic bleeding risk of continuous IV anticoagulation. This is technically simpler to manufacture than cell seeding and has shown real reductions in acute thrombosis in some clinical uses. The engineering challenges are: covalent immobilization must preserve heparin's antithrombin-binding activity (a poorly oriented or denatured coating loses efficacy); simple adsorption elutes and depletes over weeks to months, so the effect is not permanent, motivating covalent end-point attachment chemistries; and the coating must survive sterilization, storage, and the mechanical stresses of graft handling and deployment without delaminating.
Both options are complementary rather than exclusive — a heparin-bonded surface can serve as a bridging, short-term antithrombotic measure while a seeded (or, in newer approaches, in-situ recruited) endothelium develops as the durable long-term solution.
A 4 mm femoro-popliteal bypass is the clinical scenario in which this problem is most acute — exactly the size range where native vein remains standard of care today, and where a successful small-diameter synthetic graft (combining compliance-matched wall mechanics with a durable non-thrombogenic lining) would have the largest clinical impact.
